71 citations
,
November 2012 in “Expert Opinion on Drug Safety” This article reviews the reported sexual and psychological side effects of 5-alpha reductase inhibitors for benign prostatic hyperplasia, emphasizing the need for further clinical studies.
2 citations
,
September 2012 in “Pharmaceutical patent analyst” This editorial reviews recent European legal developments related to patents on second medical uses and dosage regimes, with no new research findings reported.
September 2025 in “Consilium Medicum” This study discusses the role of 5α-reductase inhibitors in managing lower urinary tract symptoms caused by benign prostatic hyperplasia and suggests their potential use in other conditions like prostate cancer chemoprevention and androgenetic alopecia treatment, emphasizing appropriate dosing to reduce surgical complications.
16 citations
,
September 2018 in “Journal of Ethnopharmacology” This review discusses the role of inheritance, androgens, and microinflammation in androgenetic alopecia and suggests some plant-based folk remedies may help address these factors but reports no new clinical results.
14 citations
,
November 2008 in “Expert opinion on drug metabolism & toxicology” This article reviews the use of finasteride for treating benign prostatic hyperplasia and its chemopreventive potential for prostate cancer, but it calls for further discussion on its preventive use in high-risk groups.